erythrocyte membrane protein band 4.1 like 1Genealiases: 4.1N · MRD11
Q-omics provides the consensus-scored EPB41L1 profile across patient tissues and cancer cell-line models. EPB41L1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EPB41L1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, EPB41L1 protein abundance shows 31,840 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where EPB41L1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EPB41L1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EPB41L1 survival associations across molecular data types. EPB41L1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EPB41L1 RNA expression–survival associations across cancer types. High EPB41L1 expression shows unfavorable associations in UVM, ACC, UCEC and PAAD, but favorable associations in KIRC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EPB41L1 RNA expression.
This table summarizes EPB41L1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 12. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for EPB41L1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EPB41L1 shows lower tumor expression in KIRC, KICH and UCEC and higher tumor expression in LIHC, STAD and CHOL. The KIRC box plot shows higher EPB41L1 RNA expression in normal versus tumor tissue (log2 FC = −0.868, t-test p < 0.001).
This table shows molecular features associated with EPB41L1 in patient tissues and cancer cell lines. In patient samples, EPB41L1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, EPB41L1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
